Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I

Food and Chemical Toxicology

Volumn 92, Issue , 2016, Pages 104-116

  Abdullah, Rozaini ^a,b   Alhusainy, Wasma ^a   Woutersen, Jasper ^a   Rietjens, Ivonne M C M ^a   Punt, Ans ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Aristolochic acid I (AAI); In vitro in vivo extrapolation; Kidney toxicity; Physiologically based kinetic (PBK) model; Physiologically based pharmacokinetic (PBPK) model; Risk assessment

Indexed keywords

ARISTOLOCHIC ACID I; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; ARISTOLOCHIC ACID; CARCINOGEN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; MOUSE; NEPHROTOXICITY; NONHUMAN; PHYSIOLOGICALLY BASED KINETIC MODEL; PREDICTION; RAT; RISK ASSESSMENT; SPECIES DIFFERENCE; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; COMPUTER SIMULATION; DRUG EFFECTS; KIDNEY; KINETICS; PATHOLOGY; PROCEDURES; TOXICITY TESTING;

ANIMALS; ARISTOLOCHIC ACIDS; CARCINOGENS; CELL SURVIVAL; COMPUTER SIMULATION; HUMANS; KIDNEY; KINETICS; MICE; MODELS, BIOLOGICAL; RATS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84962892199     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2016.03.017     Document Type: Article

References (68)

1. Arlt V.M., Schmeiser H.H., Pfeifer G.P. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 2001, 22:133-140.
2. Arlt V.M., Stiborova M., Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002, 17:265-277.
3. Balachandran P., Wei F., Lin R.C., Khan I.A., Pasco D.S. Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. Kidney Int. 2005, 67:1797-1805.
4. Berezhkovskiy L.M. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 2004, 93:1628-1640.
5. Blaauboer B.J., Hermens J., van Eijkeren J. Estimating acute toxicity based on in vitro cytotoxicity: role of biokinetic modelling. ALTEX 2006, 23:250-253.
6. Brown R., Delp M., Lindstedt S., Rhomberg L., Beliles R. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
7. Cai Y., Cai T.G. Two new aristolochic acid derivatives from the roots of Aristolochia fangchi and their cytotoxicities. Chem. Pharm. Bull. 2010, 58:1093-1095.
8. Chan W., Cui L., Xu G., Cai Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:1755-1760.
9. Chan W., Luo H.B., Zheng Y., Cheng Y.K., Cai Z. Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metabolism Dispos. 2007, 35:866-874.
10. Chen M., Gong L., Qi X., Xing G., Luan Y., Wu Y., Xiao Y., Yao J., Li Y., Xue X. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol. Sci. 2011, 122:288-296.
11. Chen M., Su M., Zhao L., Jiang J., Liu P., Cheng J., Lai Y., Liu Y., Jia W. Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. J. Proteome Res. 2006, 5:995-1002.
12. Daston G.P., Chapin R.E., Scialli A.R., Piersma A.H., Carney E.W., Rogers J.M., Friedman J.M. A different approach to validating screening assays for developmental toxicity. Birth Defects Res. Part B Dev. Reproductive Toxicol. 2010, 89:526-530.
13. EFSA European Food Safety Authority. Opinion of the scientific committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. Efsa J. 2005, 282:1-31.
14. EMEA The European Agency for the Evaluation of Medicinal products, Position Paper on the Risks Associated with the Use of Herbal Products Containing Aristolochia Species 2000, 1-10.
15. Evans M.V., Andersen M.E. Sensitivity analysis of a physiological model for 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol. Sci. 2000, 54:71-80.
16. Gillerot G., Goffin E., Moulin P., Arlt V.M., Phillips D.H., Cosyns J.P., Devuyst O. Aristolochic acid nephropathy and the peritoneum: functional, structural, and molecular studies. Kidney Int. 2003, 64:1883-1892.
17. Grollman A.P., Scarborough J., Jelakovic B. Aristolochic acid nephropathy: an environmental and iatrogenic disease. Adv. Mol. Toxicol. 2009, 3:211-227.
18. Han S.Y., Qiao J.Q., Zhang Y.Y., Lian H.Z., Ge X. Determination of n-octanol/water partition coefficients of weak ionizable solutes by RP-HPLC with neutral model compounds. Talanta 2012, 97:355-361.
19. Hsin Y.H., Cheng C.H., Tzen J.T., Wu M.J., Shu K.H., Chen H.C. Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells. Apoptosis 2006, 11:2167-2177.
20. Huang T., Chen S., Li Y., Lee J. Urinary d-lactate levels reflect renal function in aristolochic acid-induced nephropathy in mice. Biomed. Chromatogr. 2013, 27:1100-1106.
21. Huljic S., Bruske E.I., Pfitzenmaier N., O'Brien E., Dietrich D.R. Species-specific toxicity of aristolochic acid (AA) in vitro. Toxicol. Vitro 2008, 22:1213-1221.
22. Ioset J.-R., Raoelison G., Hostettmann K. Detection of aristolochic acid in Chinese phytomedicines and dietary supplements used as slimming regimens. Food Chem. Toxicol. 2003, 41:29-36.
23. IPCS Guidance Document for the Use of Data in Development of Chemical-specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability in Dose/Concentration-response Assessment 2001, World Health Organization, Geneva.
24. Kiwamoto R., Spenkelink A., Rietjens I.M.C.M., Punt A. A physiologically based in silico model for trans-2-hexenal detoxification and DNA adduct formation in human including interindividual variation indicates efficient detoxification and a negligible genotoxicity risk. Archives Toxicol. 2013, 87:1725-1737.
25. Krumbiegel G., Hallensleben J., Mennicke W., Rittmann N., Roth H. Studies on the metabolism of aristolochic acids I and II. Xenobiotica 1987, 17:981-991.
26. Kumar V., Prasad A.K., Parmar V.S. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat. Product. Rep. 2003, 20:565-583.
27. Lebeau C., Arlt V.M., Schmeiser H.H., Boom A., Verroust P.J., Devuyst O., Beauwens R. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int. 2001, 60:1332-1342.
28. Lebeau C., Debelle F.D., Arlt V.M., Pozdzik A., De Prez E.G., Phillips D.H., Deschodt-Lanckman M.M., Vanherweghem J.-L., Nortier J.L. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol. Dial. Transplant. 2005, 20:2321-2332.
29. Li J., Zhang L., Jiang Z., Shu B., Li F., Bao Q., Zhang L. Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells. Toxicol. Vitro 2010, 24:1092-1097.
30. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metabolism Dispos. 1998, 26:1202-1212.
31. Liu Q., Wang Q., Yang X., Shen X., Zhang B. Differential cytotoxic effects of denitroaristolochic acid II and aristolochic acids on renal epithelial cells. Toxicol. Lett. 2009, 184:5-12.
32. Louisse J., Bosgra S., Blaauboer B.J., Rietjens I.M.C.M., Verwei M. Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling. Archives Toxicol. 2014, 89:1135-1148.
33. Louisse J., de Jong E., van de Sandt J.J., Blaauboer B.J., Woutersen R.A., Piersma A.H., Rietjens I.M.C.M., Verwei M. The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol. Sci. 2010, 118:470-484.
34. Martena M.J., van der Wielen J.C., van de Laak L.F., Konings E.J., de Groot H.N., Rietjens I.M.C.M. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal. Bioanal. Chem. 2007, 389:263-275.
35. Martinek V., Kubickova B., Arlt V.M., Frei E., Schmeiser H.H., Hudecek J., Stiborova M. Comparison of activation of aristolochic acid I and II with NADPH: quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro Endocrinol. Lett. 2010, 32:57-70.
36. Mengs U. Acute toxicity of aristolochic acid in rodents. Archives Toxicol. 1987, 59:328-331.
37. Mengs U. Tumour induction in mice following exposure to aristolochic acid. Archives Toxicol. 1988, 61:504-505.
38. Mengs U., Lang W., Poch J.-A. The carcinogenic action of aristolochic acid in rats. Archives Toxicol. 1982, 51:107-119.
39. Mengs U., Stotzem C. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Archives Toxicol. 1993, 67:307-311.
40. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
41. Nortier J.L., Martinez M.-C.M., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., Vanherweghem J.-L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000, 342:1686-1692.
42. NTP National Toxicology Program. Final Report on Carcinogens Background Document for Aristolochic Acids. Report on Carcinogens Background Document for Aristolochic Acids 2008.
43. Pfau W., Schmeiser H.H., Wiessler M. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 1990, 11:1627-1633.
44. Pfau W., Schmeiser H.H., Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 1990, 11:313-319.
45. Priestap H.A., Torres M.C., Rieger R.A., Dickman K.G., Freshwater T., Taft D.R., Barbieri M.A., Iden C.R. Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem. Res. Toxicol. 2011, 25:130-139.
46. Punt A., Freidig A.P., Delatour T., Scholz G., Boersma M.G., Schilter B., van Bladeren P.J., Rietjens I.M.C.M. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. Toxicol. Appl. Pharmacol. 2008, 231:248-259.
47. Ren G., Huang Q., Wu J., Yuan J., Yang G., Yan Z., Yao S. Cloud point extraction-HPLC method for the determination and pharmacokinetic study of aristolochic acids in rat plasma after oral administration of Aristolochiae Fructus. J. Chromatogr. B 2014, 953:73-79.
48. Renwick A. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 1993, 10:275-305.
49. Rosenquist T.A., Einolf H.J., Dickman K.G., Wang L., Smith A., Grollman A.P. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metabolism Dispos. 2010, 38:761-768.
50. Sato N., Takahashi D., Tsuchiya R., Mukoyama T., Yamagata S.I., Satoh N., Ueda S., Chen S.M., Ogawa M., Yoshida M. Acute nephrotoxicity of aristolochic acids in mice. J. Pharm. Pharmacol. 2004, 56:221-229.
51. Schaneberg B., Khan I. Analysis of products suspected of containing Aristolochia or Asarum species. J. Ethnopharmacol. 2004, 94:245-249.
52. Schmeiser H., Schoepe K.-B., Wiessler M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 1988, 9:297-303.
53. Sharma V., McNeill J.H. To scale or not to scale: the principles of dose extrapolation. Br. J. Pharmacol. 2009, 157:907-921.
54. Shibutani S., Bonala R.R., Rosenquist T., Rieger R., Suzuki N., Johnson F., Miller F., Grollman A.P. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer 2010, 127:1021-1027.
55. Shibutani S., Dong H., Suzuki N., Ueda S., Miller F., Grollman A.P. Selective toxicity of aristolochic acids I and II. Drug Metabolism Dispos. 2007, 35:1217-1222.
56. Stiborová M., Frei E., Sopko B., Sopková K., Marková V., Laňková M., Kumstýřová T., Wiessler M., Schmeiser H.H. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD (P) H: quinone oxidoreductase. Carcinogenesis 2003, 24:1695-1703.
57. Stiborová M., Levová K., Bárta F., Shi Z., Frei E., Schmeiser H.H., Nebert D.W., Phillips D.H., Arlt V.M. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol. Sci. 2012, 125:345-358.
58. Strikwold M., Spenkelink B., Woutersen R.A., Rietjens I.M.C.M., Punt A. Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human. Archives Toxicol. 2013, 87:1709-1723.
59. Su T., Qu L., Zhang C., Cai S., Li X. Studies on pharmacodynamic characteristics of aristolochic acid I in rats. J. Chin. materia medica 2004, 29:676-681.
60. Vanhaelen M., Vanhaelen-Fastre R., But P., Vanherweghem J.-L. Identification of aristolochic acid in Chinese herbs. Lancet 1994, 343:174.
61. Vanherweghem J.-L., Tielemans C., Abramowicz D., Depierreux M., Vanhaelen-Fastre R., Vanhaelen M., Dratwa M., Richard C., Vandervelde D., Verbeelen D. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341:387-391.
62. Xiao Y., Ge M., Xue X., Wang C., Wang H., Wu X., Li L., Liu L., Qi X., Zhang Y. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 2008, 73:1231-1239.
63. Xue X., Xiao Y., Zhu H., Wang H., Liu Y., Xie T., Ren J. Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol. Dial. Transplant. 2008, 23:3074-3081.
64. Yan G.Z., Generaux C.N., Yoon M., Goldsmith R.B., Tidwell R.R., Hall J.E., Olson C.A., Clewell H.J., Brouwer K.L., Paine M.F. A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug metabolism Dispos. 2012, 40:6-17.
65. Yang H., Zheng X., Du Y., Chen Z., Zhu D., Lou Y. Kinetics of aristolochic acid I after oral administration of Radix Aristolochiae or Guanxinsuhe preparation in canines. J. Ethnopharmacol. 2011, 135:569-574.
66. Yang L., Su T., Li X.-M., Wang X., Cai S.-Q., Meng L.-Q., Zou W.-Z., Wang H.-Y. Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol. Dial. Transplant. 2012, 27:292-298.
67. Yeh Y.H., Lee Y.T., Hsieh H.S., Hwang D.F. Short-term toxicity of aristolochic acid, aristolochic acid-I and aristolochic acid-II in rats. Food Chem. Toxicol. 2008, 46:1157-1163.
68. Yuan S.Y., Yang C.R., Cheng C.L., Hsu S.L., Liao J.W., Lin C.C., Chou Y.Y., Cheng Y.W. Comparative nephrotoxicity of aristolochic acid and tetrandrine in vitro and in vivo. Int. J. Toxicol. 2011, 30:35-46.